These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 29263441)

  • 1. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.
    Mei Y; Zhao B; Basiorka AA; Yang J; Cao L; Zhang J; List A; Ji P
    Leukemia; 2018 Apr; 32(4):1023-1033. PubMed ID: 29263441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyserythropoiesis of myelodysplastic syndromes.
    Lefèvre C; Bondu S; Le Goff S; Kosmider O; Fontenay M
    Curr Opin Hematol; 2017 May; 24(3):191-197. PubMed ID: 28072603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
    Keerthivasan G; Mei Y; Zhao B; Zhang L; Harris CE; Gao J; Basiorka AA; Schipma MJ; McElherne J; Yang J; Verma AK; Pellagatti A; Boultwood J; List AF; Williams DA; Ji P
    Blood; 2014 Jul; 124(5):780-90. PubMed ID: 24891322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS; Padron E; Ebert BL; List AF
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.
    Schneider RK; Schenone M; Ferreira MV; Kramann R; Joyce CE; Hartigan C; Beier F; Brümmendorf TH; Germing U; Platzbecker U; Büsche G; Knüchel R; Chen MC; Waters CS; Chen E; Chu LP; Novina CD; Lindsley RC; Carr SA; Ebert BL
    Nat Med; 2016 Mar; 22(3):288-97. PubMed ID: 26878232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
    Talati C; Sallman D; List A
    Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Megakaryocytopoiesis in patients with myelodysplastic syndromes (MDS) with and without del(5q).
    Podolak-Dawidziak M; Geddes D; Bowen D
    Eur J Haematol; 1990 Aug; 45(2):115-6. PubMed ID: 2271049
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
    Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
    Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
    Kumar MS; Narla A; Nonami A; Mullally A; Dimitrova N; Ball B; McAuley JR; Poveromo L; Kutok JL; Galili N; Raza A; Attar E; Gilliland DG; Jacks T; Ebert BL
    Blood; 2011 Oct; 118(17):4666-73. PubMed ID: 21873545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
    Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
    Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
    Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
    Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study.
    Giagounidis AA; Haase S; Germing U; Schlegelberger B; Wilkens L; Büsche G; Kreipe HH; Wysk J; Grips KH; Grabenhorst U; Rothmann F; Lübbert M; Ganser A; Aivado M; Heinsch M; Aul C
    Ann Hematol; 2005 Jun; 84(6):389-94. PubMed ID: 15785949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic deletions in AML and MDS.
    Ebert BL
    Best Pract Res Clin Haematol; 2010 Dec; 23(4):457-61. PubMed ID: 21130407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network.
    Fang J; Barker B; Bolanos L; Liu X; Jerez A; Makishima H; Christie S; Chen X; Rao DS; Grimes HL; Komurov K; Weirauch MT; Cancelas JA; Maciejewski JP; Starczynowski DT
    Cell Rep; 2014 Sep; 8(5):1328-38. PubMed ID: 25199827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
    Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
    Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs).
    Poli A; Ratti S; Finelli C; Mongiorgi S; Clissa C; Lonetti A; Cappellini A; Catozzi A; Barraco M; Suh PG; Manzoli L; McCubrey JA; Cocco L; Follo MY
    FASEB J; 2018 Feb; 32(2):681-692. PubMed ID: 28970249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
    Buesche G; Teoman H; Schneider RK; Ribezzo F; Ebert BL; Giagounidis A; Göhring G; Schlegelberger B; Bock O; Ganser A; Aul C; Germing U; Kreipe H
    Br J Haematol; 2022 Jul; 198(1):114-130. PubMed ID: 35362549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
    Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.